文献速递角膜与眼表疾病

两种同种异体来源血液制品治疗伴角膜病变的重度干眼:多中心随机交叉临床试验

Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial.
PubMed 文献 · Br J Ophthalmol · 2019-11-19

结果显示两组角膜染色均改善,CBS组在主观症状和角膜损伤减轻方面可能更优。

要点

  • CBS与PBS滴眼液均能改善重度干眼伴角膜上皮缺损患者的体征。
  • CBS在减轻沙砾感和疼痛等主观症状方面可能优于PBS。
  • 角膜上皮损伤的改善与EGF、TGFα和PDGF含量正相关。

核心结论

  • CBS和PBS治疗均改善重度干眼伴持续性角膜上皮缺损的体征。
  • CBS在主观症状和角膜损伤减轻方面可能具有优势。

研究设计与样本

  • 滴眼液每日8次,治疗1个月;2个月后复发者交叉至另一组再治疗1个月。

主要发现

  • CBS治疗后角膜荧光素染色显著减轻更多。
  • 两组VAS和OSDI评分均下降,但CBS组沙砾感和疼痛显著更轻。
  • 上皮损伤减轻与EGF、TGFα和PDGF含量正相关;IL-13水平与症状减轻正相关。

关键数值与推荐

  • 主要结局为治疗前后角膜荧光素染色变化。
  • 次要结局包括OSDI、VAS、Schirmer I试验、泪膜破裂时间和结膜染色。
  • 统计显著性标准为p<0.05。

临床怎么用

  • 对常规治疗抵抗的重度干眼伴角膜上皮缺损,可考虑CBS或PBS滴眼液治疗。
  • CBS可能更适合以主观症状和角膜损伤为主要问题的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To compare the efficacy of cord blood and peripheral adult donor blood serum eyedrops, controlled for growth factor content, in the treatment of severe dry eye diseases (DED) resistant to conventional therapy. METHODS: This was a multicentre randomised, double-masked, cross-over clinical trial. Sixty patients diagnosed as severe DED, associated to persistent corneal epithelial defects were randomised and equally assigned to group A (treated with cord blood serum (CBS)) or group B (treated with PBS), eyedrops administered eight times/day for 1 month. Primary outcome was the pretreatment and post-treatment change in corneal fluorescein staining. Secondary outcomes included the pretreatment and post-treatment change in Ocular Surface Disease Index (OSDI) questionnaire and Visual Analogue Score (VAS) of subjective symptoms, Schirmer I test, tear break-up time and conjunctival staining. Patients with relapse in signs or symptoms after further 2 months switched to the remaining group for one additional month. Data were statistically analysed (p<0.05). RESULTS: Corneal staining was more significantly reduced after the CBS treatment, both VAS and OSDI score reduction was observed in both groups, but group A reported significantly less grittiness and pain. Nineteen patients shifted in the crossover period, the within individual comparison confirmed a better recovery in the CBS treatment period. Reduction in epithelial damage was positively associated with epidermal growth factor, transforming growth factorα and platelet-derived growth factor content. Levels of interleukins (IL-13) were positively associated with symptom decrease. CONCLUSIONS: Overall, DED signs improved after both CBS and PBS treatments, with potential advantages of CBS for subjective symptoms and corneal damage reduction. CLINICAL TRIAL REGISTRATION: NCT03064984.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Campos E, Versura P, Buzzi M, et al. Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial. Br J Ophthalmol. 2019. PMID: 31744796. doi:10.1136/bjophthalmol-2019-314859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。